This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: I28 (Other diseases of pulmonary vessels) | Special Copayment Reduction: V192 (Special copayment reduction for heart disease: 5% copayment for up to 30 days from the registration date) |
| B. Synonyms | Pulmonary arteriovenous malformation (PAVM), pulmonary artery aneurysm, pulmonary arteritis |
| C. Adult onset | Congenital pulmonary arteriovenous malformation can present from childhood but is often diagnosed in adulthood; pulmonary artery aneurysm presents mainly in adults; and pulmonary arteritis appears in adults in association with underlying diseases such as connective tissue disease. |
| 1. History | Advances in the understanding of pulmonary vascular disease, from the first description of pulmonary arteriovenous malformation in the 19th century to modern coil embolization and endovascular stent treatment |
| 2. Causes | Congenital vascular malformations (HHT-related PAVM), infection (fungal infection of the pulmonary artery), trauma, autoimmune vasculitis, and pulmonary artery aneurysm due to hypertension |
| 3. Genetics | ENG (endoglin), ACVRL1 (ALK-1), and SMAD4 variants in HHT-associated PAVM; BMPR2 variants are the most important in pulmonary arterial hypertension |
| 4. General epidemiology | Prevalence of PAVM about 2-3 per 100,000; mostly associated with HHT (15-50% of HHT patients); pulmonary artery aneurysm is a rare disease |
| 5. Pathophysiology | PAVM: direct pulmonary artery-pulmonary vein connection without capillaries, causing a left-right shunt of deoxygenated blood; pulmonary artery aneurysm: focal dilation due to vessel wall weakening |
| 6. Symptoms | Dyspnea, cyanosis, hemoptysis, stroke or brain abscess due to paradoxical embolism; life-threatening hemoptysis and hemothorax occur when a pulmonary artery aneurysm ruptures |
| 7. Signs | Cyanosis, clubbing, chest vascular bruit (machinery or continuous), hypoxemia, simple nodular findings on chest X-ray |
| 8. Screening | Screening contrast echocardiography in patients with a family history of HHT; chest CT is effective for PAVM screening |
| 9. Diagnosis | CT angiography (CTA) and pulmonary angiography are essential for definitive diagnosis and treatment planning of PAVM and pulmonary artery aneurysm |
| 10. Treatment | Transcatheter coil embolization is the first-line treatment for PAVM; endovascular stent or surgery for pulmonary artery aneurysm; treatment of the underlying disease for pulmonary arteritis |
| 11. Prognosis | The prognosis of PAVM after embolization is good, but long-term follow-up is needed because of the risk of recanalization; ruptured pulmonary artery aneurysm has high mortality |
| 12. Prevention | Regular screening of HHT patients, restriction of air travel and diving when PAVM is diagnosed, prevention of paradoxical embolism through prophylactic embolization |
| 13. References | Faughnan ME, et al. International guidelines for the diagnosis and management of hereditary haemorrhagic telangiectasia … and 9 other papers |
Among other diseases of pulmonary vessels (ICD I28), the history of the most clinically important, pulmonary arteriovenous malformation (PAVM), dates back to the late 19th century. In 1897, Churton first described the pathological findings of PAVM, and in 1939 Smith and Horton reported the first clinical case. Initially it was regarded as a rare anatomical curiosity, but from the 1950s onward, as its association with hereditary hemorrhagic telangiectasia (HHT, Osler-Weber-Rendu syndrome) was revealed, it began to be understood as a vascular complication of a genetic disease.
In the 1960s-1970s, surgical resection was the only treatment, but in 1977 Terry and White first reported transcatheter coil embolization, opening the era of minimally invasive treatment. Subsequently, advances in embolic materials such as coils and vascular occlusion devices (Amplatzer vascular plug, AVP) greatly improved technical success rates and safety. The genetic link between HHT and PAVM was elucidated with advances in molecular genetics in the 1990s: in 1994 McAllister et al. first reported ENG gene variants, and ACVRL1 variants were subsequently identified.
Pulmonary artery aneurysm (PAA) is an extremely rare disease that has historically been described in the literature in the form of sporadic case reports associated with various causes such as Behçet disease, infective endocarditis, congenital heart malformations, and pulmonary arterial hypertension. In 1947, Hughes-Stovin syndrome (a combination of pulmonary artery aneurysm + peripheral venous thrombosis) was described, and it is understood as a variant of Behçet disease. Pulmonary arteritis is a secondary disease arising from pulmonary vascular involvement by large vessel vasculitis (Takayasu arteritis, giant cell arteritis), small vessel vasculitis (microscopic polyangiitis, granulomatosis with polyangiitis), and systemic autoimmune diseases (SLE, RA, systemic sclerosis), and its understanding has deepened along with advances in autoimmune disease research.
Since Faughnan et al. published international management guidelines for HHT-related PAVM in 2006, revised editions were published in 2011 and 2020, establishing standardized diagnostic and treatment algorithms. With advances in CT technology since the 1990s, the accuracy of noninvasive diagnosis and size measurement of pulmonary arteriovenous malformations has greatly improved, and multidetector CT angiography (MDCTA) is now established as the standard tool for PAVM screening and follow-up.
Recent studies have highlighted the problem of recanalization after PAVM embolization and the resulting persistent risk of cerebral complications. Studies are accumulating showing that new second- and third-generation Amplatzer vascular plug devices and techniques combining coils and plugs are more effective in preventing recanalization. The importance of a multidisciplinary approach (pulmonology, radiology, cardiology, genetic medicine) is increasingly emphasized across pulmonary vascular disease.
The pulmonary vascular diseases in the ICD I28 category have diverse causes. About 70-90% of pulmonary arteriovenous malformations (PAVM, I28.0) are congenital malformations associated with hereditary hemorrhagic telangiectasia (HHT). HHT is an autosomal dominant disease in which abnormal vascular development results from mutations in genes related to the TGF-β signaling pathway, such as ENG and ACVRL1. PAVM develops in 15-50% of HHT patients, and about 80% of PAVMs are found in HHT patients. The remaining 10-30% are caused by idiopathic, traumatic, hepatopulmonary syndrome due to liver cirrhosis, metastatic vascular disease, and others.
The causes of pulmonary artery aneurysm (I28.1) are diverse. The most common cause is mechanical dilation of the vessel wall due to pulmonary arterial hypertension, followed by Behçet disease (immune-mediated destruction of the vessel wall), congenital heart malformations (post-stenotic dilation of the pulmonary artery), infective endocarditis or vessel wall infection (mycotic aneurysm due to fungi or bacteria), connective tissue diseases (Marfan syndrome, Ehlers-Danlos syndrome), and trauma. Hughes-Stovin syndrome is a rare syndrome in which pulmonary artery aneurysm is accompanied by peripheral venous thrombosis and is classified as a form of Behçet disease.
Causes of pulmonary arteritis (I28.8) include vascular involvement in large vessel vasculitis [Takayasu arteritis (pulmonary artery involvement about 50-80%), giant cell arteritis], small vessel vasculitis [granulomatosis with polyangiitis (GPA, formerly Wegener), microscopic polyangiitis (MPA), eosinophilic granulomatosis with polyangiitis (EGPA)], and systemic autoimmune diseases [SLE, systemic sclerosis (SSc), rheumatoid arthritis]. As infectious causes, tuberculosis, syphilis, and fungal infections (Aspergillus, Mucor) can cause pulmonary vasculitis. Other diseases of pulmonary vessels (I28.8), such as pulmonary vascular stenosis, pulmonary vascular rupture, and pulmonary vascular endarteritis, can also occur as primary or secondary conditions.
The genetics of HHT in relation to pulmonary arteriovenous malformations is the best studied. HHT follows an autosomal dominant inheritance pattern and is passed on to offspring in about 50% of individuals with a gene mutation. To date, there are mainly three genes associated with HHT: HHT type 1 due to ENG (endoglin gene) mutations, HHT type 2 due to ACVRL1 (ALK-1, activin receptor-like kinase 1) mutations, and the HHT-JP type (with juvenile gastrointestinal polyposis) due to SMAD4 mutations. ENG and ACVRL1 are components of the receptor complex of the TGF-β/BMP signaling pathway, and their loss of function leads to abnormal vascular formation.
An association between PAVM development and HHT genotype has been reported. Patients with HHT1 (ENG variants) have a higher incidence of pulmonary PAVM than patients with HHT2 (ACVRL1 variants) (30-50% vs. 15-25%), and PAVM occurs rarely in SMAD4-related HHT. In some families, causative genes other than the three known genes are presumed to exist (HHT3 and HHT4 classifications exist), and identification of these genes is ongoing.
In pulmonary artery aneurysm associated with pulmonary arterial hypertension, BMPR2 (bone morphogenetic protein receptor type 2) gene variants are important. Like ACVRL1, BMPR2 is a component of the TGF-β/BMP signaling pathway, and BMPR2 variants are identified in about 70-80% of idiopathic and heritable pulmonary arterial hypertension (IPAH/HPAH). BMPR2 variants impair the mechanism that inhibits proliferation of pulmonary artery smooth muscle cells, leading to vascular remodeling and increased pulmonary artery pressure.
In Behçet disease-related pulmonary artery aneurysm, HLA-B51 is known as a strong genetic susceptibility factor, and HLA-B51 carriers have a 2-10-fold increased risk of developing Behçet disease. This is presumed to be because the specificity of the HLA molecules involved in antigen presentation is involved in determining the targets of autoreactive immune responses. In pulmonary vascular disease related to autoimmune vasculitis, variants of immune regulatory genes such as PTPN22, CTLA4, and IL-10 also affect susceptibility to the disease.
Other diseases of pulmonary vessels generally fall into the category of rare diseases. The population-based prevalence of pulmonary arteriovenous malformation (PAVM) is estimated at about 2-3 per 100,000, but considering the prevalence of HHT (about 1/5,000-1/8,000), it may actually be higher. Precise prevalence data for Korea are lacking, but based on HHT patient registry programs and rare disease databases, it is estimated to be similar to or slightly lower than in Western countries. There are reports that PAVM occurs about 1.5-2 times more commonly in women than in men, but this may relate to promotion of PAVM growth in women (possibly estrogen-related) rather than to sex differences in HHT prevalence.
Important events in the natural history of PAVM are stroke and brain abscess due to paradoxical embolism. Cerebral complications are experienced by 10-30% of HHT patients with PAVM, because bacteria or thrombi bypass the pulmonary capillary circulation, which acts as a filter, and enter the systemic circulation directly. Even in HHT patients without PAVM, cerebral arteriovenous malformations may be present in about 10-20%, posing a risk of neurological complications.
Pulmonary artery aneurysm (PAA) is very rare, with fewer than about 400 cases reported worldwide. The most common cause is pulmonary arterial hypertension, and the diameter-based diagnostic threshold is usually defined as a main pulmonary artery diameter >29mm (men) or >27mm (women). Behçet disease-related pulmonary artery aneurysm occurs predominantly in men in their 20s-30s. The prevalence of pulmonary arteritis is directly linked to the prevalence of the underlying vasculitis or autoimmune disease, and there are reports that pulmonary artery involvement in Takayasu arteritis is identified in about 50-80%.
The mechanism of pulmonary arteriovenous malformation (PAVM) is the formation of an abnormal shunt vessel between the pulmonary artery and pulmonary vein that bypasses the normal capillary circulation. Normally, the pulmonary capillaries bring pulmonary arterial blood into contact with alveolar gas for sufficient time to achieve oxygenation, while also acting as a filter that removes foreign material such as microthrombi, bacteria, and air bubbles. In PAVM, blood flows directly from the pulmonary artery to the pulmonary vein without this capillary circulation, so unoxygenated blood enters the left heart.
The hemodynamic consequences of PAVM are twofold. First, hypoxemia due to the right-to-left shunt: because deoxygenated blood enters the systemic circulation, arterial oxygen partial pressure decreases. It improves somewhat with supplemental oxygen but is not fully corrected. Second, loss of the filter function of the pulmonary capillaries: fine particles 8μm or more in diameter (bacteria, thrombi, air bubbles) can enter the systemic circulation directly without passing through the pulmonary capillaries, raising the risk of paradoxical embolism (stroke, brain abscess) and air embolism (decompression sickness).
The mechanism of pulmonary artery aneurysm is the interaction between structural weakening of the vessel wall and sustained pressure load. When pulmonary arterial hypertension is the main cause, sustained pressure load leads to remodeling and weakening of the elastic fibers (elastin) and collagen fiber network, impairing the structural integrity of the vessel wall. In Behçet disease-related pulmonary artery aneurysm, full-thickness necrosis of the vessel wall (panvasculitis) due to immune complex deposition, complement activation, and inflammatory cell infiltration is the key mechanism of aneurysm formation. The risk of rupture increases with aneurysm size and growth rate.
The mechanism of pulmonary arteritis differs depending on the underlying autoimmune disease or infection, but an immune-mediated inflammatory response against the vessel wall is commonly central. Infiltration of the vessel wall by T cells, B cells, and macrophages, endothelial dysfunction, and occlusion of the vessel lumen lead to increased pulmonary arterial resistance and ischemic injury of the pulmonary vasculature. In Takayasu arteritis, CD8+ T cell- and NK cell-mediated adventitial fibrosis and intimal proliferation, and in GPA, ANCA (antineutrophil cytoplasmic antibody)-mediated vascular injury are the main mechanisms.
Symptoms of pulmonary arteriovenous malformation (PAVM) range from asymptomatic to serious complications depending on the size and number of shunts. About 30-50% are discovered incidentally on imaging without symptoms. When shunts are large or multiple, dyspnea (especially platypnea, worsening with exercise or in the upright position), cyanosis, and generalized fatigue appear. Platypnea, in which dyspnea worsens in the upright position, is explained by the mechanism of increased blood flow to PAVMs located in the lower lungs.
Hemoptysis can occur when a PAVM ruptures and is particularly dangerous during pregnancy. During pregnancy, increased blood volume and vasodilation cause PAVMs to grow and increase the risk of rupture, making it an important cause of maternal death. Neurological complications due to paradoxical embolism are one of the most important clinical problems of PAVM. Stroke (hemiplegia, speech disturbance, visual field defects), transient ischemic attack (TIA), and migraine (present in about 50%) can occur, and brain abscess develops when oral bacteria bypass the pulmonary filter and enter the brain.
Symptoms of pulmonary artery aneurysm are often absent until rupture, but upon rupture, massive hemoptysis, hemothorax, severe dyspnea, hypotension, and shock develop abruptly and are life-threatening. Recurrent hemoptysis is characteristic of Behçet disease-related pulmonary artery aneurysm. Symptoms of pulmonary arteritis may include dyspnea, exercise intolerance, and chest pain together with systemic symptoms of the underlying disease (fever, weight loss, arthralgia, rash). When the pulmonary artery is involved in Takayasu arteritis, symptoms of pulmonary hypertension may appear.
Characteristic physical findings of pulmonary arteriovenous malformation include cyanosis and clubbing, reflecting chronic hypoxemia. Depending on the location of the PAVM, a continuous vascular murmur (continuous machinery murmur) or a systolic/diastolic murmur may be heard on chest auscultation. The murmur tends to intensify on inspiration. If pulse oxygen saturation is measured low even at rest, or a paradoxical pattern is observed in which it is higher lying down than sitting (orthodeoxia: decrease in the upright position), PAVM is strongly suggested.
When associated with HHT, telangiectasia is observed on the skin and mucous membranes, appearing as red spots mainly on the lips, tongue, fingers, toes, and face. A history of recurrent nosebleeds (epistaxis) is the most common first symptom of HHT. Hepatomegaly or a hepatic vascular bruit suggests accompanying hepatic arteriovenous malformation.
Pulmonary artery aneurysm is difficult to diagnose by physical findings alone. In large pulmonary artery aneurysms, a mass shadow may appear on chest X-ray, and upon rupture, decreased breath sounds (hemothorax) appear on chest auscultation. In pulmonary arteritis, systemic findings of the underlying vasculitis (skin rash, joint swelling, decreased renal function, sinonasal lesions, etc.) are present, and on auscultation an accentuated P2 or split S2 reflecting increased pulmonary vascular resistance may appear.
Screening for pulmonary arteriovenous malformations is mainly performed in HHT patients or individuals with a family history of HHT. When an HHT diagnosis (Curaçao criteria: 3 or more of epistaxis, cutaneous telangiectasia, visceral malformations, family history) is confirmed or suspected, contrast echocardiography is recommended as the first-line screening test for pulmonary PAVM. After intravenous injection of agitated saline, the appearance of microbubbles in the left atrium within 3-5 cycles is judged as a positive pulmonary shunt.
If contrast echocardiography is positive, chest CT (thin-section CT) is performed to evaluate the location, size, feeding artery diameter, and number of PAVMs. A feeding artery diameter ≥3mm is classified as an indication for embolization treatment. Pulse oximetry has low sensitivity and is insufficient as a standalone screening tool, but the pattern of oxygen saturation decrease during exercise is used as an adjunct in screening. Elevated blood hemoglobin (compensation for chronic hypoxemia) can also be a clue in screening.
Screening for pulmonary artery aneurysm is performed by tracking changes in pulmonary artery diameter with regular chest CT or echocardiography in patients with pulmonary arterial hypertension, Behçet disease, or connective tissue disease. If the main pulmonary artery diameter is 29mm or more, the possibility of pulmonary artery aneurysm is considered and further evaluation is performed. Screening for pulmonary arteritis is performed by assessing pulmonary symptoms and pulmonary function abnormalities during regular checkups for the underlying autoimmune disease.
CT angiography (CTA) is a key test for definitive diagnosis and morphological evaluation of pulmonary arteriovenous malformations and pulmonary artery aneurysms. On CTA, a PAVM is identified as a three-part structure of feeding artery, dilated sac-like lesion or direct connecting channel (fistula), and draining vein. It is classified as simple (one feeding artery) or complex (two or more feeding arteries). A pulmonary artery aneurysm appears on CTA as focal dilation or a sac-like structure of the pulmonary artery, and its size, location, and related vessels and cardiac structures can be evaluated.
Selective pulmonary angiography is an invasive test performed at the same time as the embolization procedure and is used to evaluate the detailed anatomical structure of feeding vessels and to plan embolization. Digital subtraction angiography (DSA) can precisely visualize even small feeding vessels. Measurement of pulmonary artery pressure is important for assessing the severity of pulmonary arterial hypertension and determining treatment strategy.
Echocardiography (including Doppler) is essential for evaluating the presence of pulmonary arterial hypertension, right ventricular function, and tricuspid regurgitation velocity (estimation of pulmonary artery systolic pressure). Magnetic resonance angiography (MRA) can evaluate vascular structures without radiation exposure, making it useful in pregnant women and patients requiring repeated examinations. For the diagnosis of pulmonary arteritis, ANCA (c-ANCA/PR3, p-ANCA/MPO), ANA, anti-dsDNA, complement levels, and Behçet disease-specific tests (HLAB51, pathergy test) are used. Tissue examination (transbronchial lung biopsy or surgical biopsy) is considered for definitive diagnosis in pulmonary vascular disease of unknown cause.
The first-line treatment of pulmonary arteriovenous malformation (PAVM) is transcatheter coil embolization. Treatment is recommended for all PAVMs with a feeding artery diameter ≥3mm because of the risks of paradoxical embolism, hemoptysis, and growth. Vascular occlusion devices such as coils (fibered detachable coil) and the Amplatzer vascular plug (AVP)-II/IV are used, and the technical success rate reaches 90-95%. For multiple PAVMs, staged embolization is performed. CT follow-up is needed after embolization, and additional procedures are performed in cases of recanalization (15-20%) or development of new PAVMs.
When embolization is impossible or has failed, or when the PAVM is too large to be treated with coils, surgical resection (segmental or lobar resection) is performed. When hemoptysis due to PAVM or a rapid increase in shunting occurs during pregnancy, embolization in the second trimester is considered first. In women with HHT planning pregnancy, prior embolization of all treatable PAVMs is recommended. Pulmonary artery aneurysm is treated with endovascular stent placement or surgery depending on the risk of rupture. In Behçet disease-related pulmonary artery aneurysm, treatment of the underlying disease with corticosteroids and immunosuppressants (cyclophosphamide) must come first, and in ruptured pulmonary artery aneurysm, emergency embolization is the first measure. Pulmonary arteritis is treated with standard immunosuppressive therapy for the underlying autoimmune disease or vasculitis (steroids, methotrexate, azathioprine, cyclophosphamide, rituximab, etc.).
Pulmonary arteriovenous malformations generally have a good prognosis when treated with appropriate embolization. After embolization, oxygen saturation improves and the risk of paradoxical embolism decreases. However, the recanalization rate reaches 15-20%, in which case additional procedures are needed. Because untreated PAVM patients have a high risk of neurological complications (stroke, brain abscess) due to paradoxical embolism, early treatment is emphasized. Long-term follow-up is needed in patients with multiple PAVMs associated with HHT, with surveillance for the development of new PAVMs and growth of existing ones.
Pulmonary artery aneurysm has very high mortality from massive hemoptysis upon rupture, and the 5-year mortality of untreated Behçet disease-related pulmonary artery aneurysm reaches 30-50%. Prognosis can be improved with active immunosuppressive therapy and endovascular or surgical treatment, but long-term follow-up is needed because of the risk of recurrence. The prognosis of pulmonary arteritis depends on the type of underlying disease and treatment response, and progression of pulmonary vascular damage can be suppressed with early diagnosis and appropriate immunosuppressive therapy.
The most important strategy for preventing complications of pulmonary arteriovenous malformations is systematic screening of HHT patients and families. PAVM screening (contrast echocardiography or chest CT) is performed in all first-degree relatives of patients diagnosed with HHT to detect PAVMs before symptoms appear and to perform prophylactic embolization. This can prevent stroke and brain abscess due to paradoxical embolism.
As a measure to prevent complications in PAVM patients, using air-free IV access in all medical procedures (including dental procedures) is important, because microbubbles can enter the systemic circulation directly through the PAVM and cause air embolism. Diving sports (scuba diving) are contraindicated because of the risk of decompression sickness. Prophylactic antibiotics before dental procedures are recommended in some guidelines to prevent paradoxical brain abscess due to oral bacteria. Pregnant HHT patients undergo PAVM evaluation by a specialist before pregnancy and embolization if necessary. Prevention of pulmonary artery aneurysm is achieved through early diagnosis and active treatment of the underlying disease (Behçet disease, pulmonary arterial hypertension).
Faughnan ME, Mager JJ, Hetts SW, et al. Second International Guidelines for the Diagnosis and Management of Hereditary Hemorrhagic Telangiectasia. Annals of Internal Medicine. 2020;173(12):989-1001. DOI: 10.7326/M20-1443. PMID: 32894695.
Shovlin CL, Guttmacher AE, Buscarini E, et al. Diagnostic criteria for hereditary hemorrhagic telangiectasia (Rendu-Osler-Weber syndrome). American Journal of Medical Genetics. 2000;91(1):66-67. DOI: 10.1002/(sici)1096-8628(20000306)91:1. PMID: 10751092.
Cottin V, Plauchu H, Bayle JY, et al. Pulmonary arteriovenous malformations in patients with hereditary hemorrhagic telangiectasia. American Journal of Respiratory and Critical Care Medicine. 2004;169(9):994-1000. DOI: 10.1164/rccm.200310-1359OC. PMID: 14962820.
Swanson KL, Prakash UBS, Stanson AW. Pulmonary arteriovenous fistulas: Mayo Clinic experience, 1982-1997. Mayo Clinic Proceedings. 1999;74(7):671-680. DOI: 10.4065/74.7.671. PMID: 10405695.
Shovlin CL. Hereditary haemorrhagic telangiectasia: pathophysiology, diagnosis and treatment. Blood Reviews. 2010;24(6):203-219. DOI: 10.1016/j.blre.2010.07.001. PMID: 20870325.
Hamdullahpur F, Sancak A, Unal NG, et al. Pulmonary artery aneurysms in Behcet's syndrome. Chest. 2004;125(4):1505-1510. DOI: 10.1378/chest.125.4.1505. PMID: 15078770.
Humbert M, Kovacs G, Hoeper MM, et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. European Heart Journal. 2022;43(38):3618-3731. DOI: 10.1093/eurheartj/ehac237. PMID: 36017548.
Lane KB, Machado RD, Pauciulo MW, et al. Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension. Nature Genetics. 2000;26(1):81-84. DOI: 10.1038/79226. PMID: 10973254.
McAllister KA, Grogg KM, Johnson DW, et al. Endoglin, a TGF-beta binding protein of endothelial cells, is the gene for hereditary haemorrhagic telangiectasia type 1. Nature Genetics. 1994;8(4):345-351. DOI: 10.1038/ng1294-345. PMID: 7894484.
Chung MK, Shim WH, Cho SY, et al. Clinical characteristics and prognosis of pulmonary arteriovenous malformations. Korean Circulation Journal. 2020;50(8):722-731. DOI: 10.4070/kcj.2019.0382. PMID: 32656988.